128.07 0.00 (0.00%)
After hours: 4:53PM EDT
|Bid||127.91 x 800|
|Ask||128.53 x 1100|
|Day's Range||127.16 - 129.36|
|52 Week Range||101.42 - 142.50|
|Beta (3Y Monthly)||0.89|
|PE Ratio (TTM)||31.12|
|Earnings Date||Jul 23, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||149.29|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 20) Kaleido Biosciences Inc (NASDAQ: KLDO ) Down In The ...
PALO ALTO, Calif., May 20, 2019 /PRNewswire/ -- Taking an important step to accelerate innovation of new multidisciplinary solutions to address the growing global cancer burden, Varian Medical Systems (VAR) today announced it has entered into a definitive agreement to acquire Cancer Treatment Services International (CTSI) for $283 million. Privately held, CTSI operates the American Oncology Institute in Hyderabad and 10 multidisciplinary—radiation, medical and surgical oncology— cancer centers across the Indian subcontinent as well as a U.S.-based Oncology Solutions division that provides cancer care professional services to healthcare providers worldwide.
PALO ALTO, Calif., May 16, 2019 /PRNewswire/ -- Varian (VAR) today announced preliminary estimates of the incremental gross impact of new tariffs. Over the past week, the US increased tariffs on certain goods (US List 3), and imposed new tariffs on certain other goods (US List 4), imported from China. Subsequently, China implemented a retaliatory increase in tariffs on certain goods imported from the US (responding to the US List 3 action). Management has preliminarily estimated the gross impact of these new tariffs to be in the range of $3M to $5M.
The cyclotron is a core piece of equipment in the ProBeam proton therapy system. This installation marks a key milestone for the first proton therapy center in Singapore, ASEAN, Australia and New Zealand.
PALO ALTO, Calif., May 13, 2019 /PRNewswire/ -- Varian (VAR) today announced it was selected by Port Moresby General Hospital (PMGH) in Papua New Guinea to equip its cancer treatment center with the Halcyon™ radiotherapy system, as well as the ARIA® oncology information system and Eclipse™ treatment planning system. The Halcyon system simplifies and enhances virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT), including improved patient comfort and shortening the time from installation to first-treatment without sacrificing quality. The Halcyon system is well-suited to treat a majority of cancer patients, offering advanced treatments for lung, prostate, breast, head & neck, and many other forms of cancer.
The CyberHeart acquisition secures significant intellectual property/patents that cover the use of radiation in the heart. Early positive clinical evidence suggests that cardiac radioablation has the potential to offer hope to patients with intractable cardiac arrhythmias. Acquisitions are a critical step in Varian's long-term strategy to become a global leader in multi-disciplinary, integrated cancer solutions as well as other applications of radiation medicine.
PALO ALTO, Calif. , May 9, 2019 /PRNewswire/ -- Following a comprehensive evaluation by Sykehusbygg HF Norway and regional health authorities, Varian (NYSE: VAR) was selected to equip two proton therapy ...
PALO ALTO, Calif. and JINAN, China, May 9, 2019 /PRNewswire/ -- Varian (VAR) today announced it has signed a strategic cooperation framework agreement with Shandong Cancer Hospital in China, for proton therapy clinical application and research. The agreement signing ceremony on May 9th in Jinan, China was attended by Professor Yu Jinming, academician of the Chinese Academy of Engineering and president of Shandong Cancer Hospital & Institute, Kolleen Kennedy, president, Proton Solutions and chief growth officer of Varian, and Dr. Zhang Xiao, vice president and head of Varian Greater China.
PALO ALTO, Calif. , May 7, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced that it will be attending the UBS Global Healthcare Conference ( May 20-22 ) and the 2019 RBC Capital Markets Healthcare ...
Varian Medical Systems Inc NYSE:VARView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for VAR with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting VAR. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $790 million over the last one-month into ETFs that hold VAR are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! As Varian Medical Systems, Inc. (NYSE:VAR) announced its earnings release on 29 March 2019...
PALO ALTO, Calif. and CAPE TOWN, South Africa, April 30, 2019 /PRNewswire/ -- Varian (VAR) announced Groote Schuur Hospital in Cape Town, South Africa is the first hospital in Africa to deliver High Dose Rate (HDR) brachytherapy treatments with the Bravos™ afterloader system. Bravos is an integrated system designed to improve the patient and clinic experience by simplifying brachytherapy treatments and providing greater workflow efficiency. HDR brachytherapy involves delivering radiotherapy by temporarily placing a tiny radioactive source directly into the tumor or other targeted area.
PALO ALTO, Calif., April 29, 2019 /PRNewswire/ -- Varian (VAR) today announced Ofuna Chuo Hospital, Kamakura City, Kanagawa Prefecture, Japan is the first clinic in the country to begin treating cancer patients using the Halcyon™ radiotherapy system. The Halcyon system simplifies and enhances virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT), including improved patient comfort and shortening the time from installation to first-treatment without sacrificing quality.
PALO ALTO, Calif. , April 26, 2019 /PRNewswire/ -- Bringing together a global community of clinicians and scientists from leading cancer clinics to develop best practices for adaptive radiotherapy based ...
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs Wednesday. Down In The Dumps (Biotech stocks hitting 52-week lows on April ...